AstraZeneca Says Brilinta Premium Pricing Merited Based On Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
During its quarterly earnings call, the pharma pointed out that international reimbursement decisions have supported premium pricing over Plavix.
You may also be interested in...
For Effient And Brilinta, A Formidable Competitor Grows More So
Plavix was a tough competitor before it went generic; now that cheap versions of the clot-buster are available, the market will prove even more challenging for the remaining branded antiplatelet drugs.
AstraZeneca Prepares For U.S. Statin Market Shake-Up As Lipitor Goes Generic
Pricing pressure on AstraZeneca's Crestor expected from the arrival of generic atorvastatin in the U.S. in the fourth quarter.
AstraZeneca Prepares For U.S. Statin Market Shake-Up As Lipitor Goes Generic
Pricing pressure on AstraZeneca's Crestor expected from the arrival of generic atorvastatin in the U.S. in the fourth quarter.